A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma’s dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.
Financial Summary
| Share Statistics | SPHRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $245.4 | $646.9 | 29% |
|
| Shares Out (Mil) | 290.9 | 43.5 | 82% |
|
| Institutional Ownership | 26.1% | 85.0% | 11% |
|
| Float (Mil) | 350.3 | 46.7 | 81% |
|
| Beta | 0.76 | 0.73 | 45% |
|
| Avg Daily Volume (000s) | 1 | 272 | 4% |
|
| Price Change (52-week) |
467.9% | 67.9% | 99% |
|
| Growth | SPHRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.6% | 6.7% | 88% |
|
| Net Income (5yr) | 18.9% | (1.6%) | 71% |
|
| EPS (5yr) | 17.7% | 14.9% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.3%) | (15.1%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SPHRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $317 | 8% |
|
| Net Income (TTM) (Mil) | ($5) | ($11) | 33% |
|
| EPS (TTM) | ($0.012) | ($0.700) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($7) | 29% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $6 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $229 | $614 | 27% |
|
| Valuation | SPHRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.74 | na |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SPHRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 6.1% | 68.1% | 7% |
|
| Net Margin | (58.9%) | (2.3%) | 10% |
|
| ROA | (34.6%) | (25.4%) | 15% |
|
| ROE | (47.0%) | (21.0%) | 16% |
|
| Liabilities to Assets | 27.6% | 31.8% | 19% |
|
| F-Score | na | 3 | na |
|
Starpharma Holdings Limited did not pass any screens on 8/28/2026.
